Biofrontera Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the SEC on November 13, 2026, reporting a net loss of $6.4 million and product revenues of $9.1 million for the third quarter.

Key Highlights

  • Product revenues, net: $9,070 thousand for Q3 2026, up from $6,988 thousand in Q3 2025, according to the filing.
  • Net loss: $6,423 thousand for the three months ended September 30, 2026, compared to $6,649 thousand in the same period of 2025.
  • Nine-month net loss: $11,779 thousand for the nine months ended September 30, 2026, versus $16,176 thousand in the first nine months of 2025.
  • Accumulated deficit: $139,724 thousand as of September 30, 2026, up from $127,945 thousand as of December 31, 2025.
  • Total stockholders' deficit: $(243) thousand as of September 30, 2026, compared to stockholders' equity of $10,480 thousand at December 31, 2025.
  • Shares outstanding: 17,949,000 common shares as of November 11, 2026, up from 11,648,323 at December 31, 2025, reflecting preferred stock conversions during the period.
  • Cash and cash equivalents: $3,218 thousand as of September 30, 2026, down from $6,392 thousand at December 31, 2025.

Biofrontera's Q3 2026 Financial Results: Revenue Growth Amid Continued Losses

According to the filing, Biofrontera Inc. (NASDAQ:BFRI) reported product revenues, net, of $9,070 thousand for the three months ended September 30, 2026, an increase from $6,988 thousand in the comparable prior-year quarter. For the nine months ended September 30, 2026, product revenues, net, totaled $31,157 thousand, compared to $24,605 thousand for the same period in 2025. The company is classified as a smaller reporting company and an emerging growth company.

Total operating expenses for Q3 2026 were $15,567 thousand, resulting in a loss from operations of $6,497 thousand, the filing disclosed. Selling, general and administrative expenses were $12,461 thousand in the quarter, compared to $10,047 thousand in Q3 2025. The filing also reported patent remediation expense of $306 thousand in Q3 2026, with no comparable charge in Q3 2025. Research and development expenses were $450 thousand for the quarter versus $854 thousand in Q3 2025. The basic and diluted loss per common share was $(0.42) for Q3 2026, compared to $(0.62) in Q3 2025, based on weighted-average common shares outstanding of 15,280,526 and 10,776,739, respectively.

On the balance sheet, the filing reported total assets of $21,466 thousand as of September 30, 2026, down from $28,564 thousand at December 31, 2025. Total liabilities rose to $21,709 thousand from $18,084 thousand over the same period. Accounts payable increased to $6,896 thousand from $1,855 thousand. The company carried convertible notes payable, net, of $4,749 thousand as of September 30, 2026. During the nine-month period, the company converted various series of preferred stock into common stock, and also converted convertible notes into 296,505 shares of common stock, recognizing $227 thousand in additional paid-in capital from that conversion, according to the filing.

What Was Disclosed

Biofrontera Inc. filed its quarterly report covering the period ended September 30, 2026, disclosing Q3 and year-to-date revenue, operating losses, balance sheet changes, and share activity including preferred stock conversions and an increase in common shares outstanding.